公开(公告)号：US20100183630A1

公开(公告)日：2010-07-22

申请号：US11922881

申请日：2006-06-29

申请人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

发明人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  G01N33/574 ,  A61P35/04

CPC分类号： G01N33/57419 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/4748 ,  G01N2500/04

摘要： Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-005蛋白的表达与癌症相关，并且过度表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-005与异常发育和生长相关，并且可用作鉴定抗癌药物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-005表达或活性的化合物的方法，包括：使候选化合物与TAT-005接触并检测所述化合物与所述TAT-005之间是否存在结合，或 检测TAT-005表达或活性的变化。 还包括用于鉴定调节TAT-005表达或活性的化合物的方法，包括：向细胞或细胞群体施用化合物，并检测TAT-005表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20060287834A1

公开(公告)日：2006-12-21

申请号：US11424736

申请日：2006-06-16

申请人： Paul Kearney ,  Kossi Lekpor ,  Sajani Swamy ,  Heather Butler ,  Kevin Eng ,  Clive Hayward ,  Joanna Hunter ,  Gregory Opiteck ,  Michael Schirm

发明人： Paul Kearney ,  Kossi Lekpor ,  Sajani Swamy ,  Heather Butler ,  Kevin Eng ,  Clive Hayward ,  Joanna Hunter ,  Gregory Opiteck ,  Michael Schirm

IPC分类号： G06F19/00

CPC分类号： G01N33/6848 ,  G01N30/7233 ,  G01N30/8686 ,  G01N30/8693 ,  G01N2030/8831

摘要： Systems, methods, computer programming product, and databases for virtual mass spectrometry (VMS) enable the identification of polypeptides in samples without acquisition of MS/MS fragmentation spectra. Methods according to the invention employ databases containing records corresponding to polypeptides potentially present in samples. In addition to identifying polypeptides, such databases may be used for other purposes, including for example to correct experimental data, e.g., for analytical systemic errors.

摘要翻译： 用于虚拟质谱（VMS）的系统，方法，计算机程序产品和数据库使得能够在样本中鉴定多肽，而无需采集MS / MS碎片谱。 根据本发明的方法使用包含对应于可能存在于样品中的多肽的记录的数据库。 除了鉴定多肽之外，这样的数据库可以用于其他目的，包括例如校正实验数据，例如用于分析系统误差。

公开(公告)号：US20070106065A1

公开(公告)日：2007-05-10

申请号：US11344933

申请日：2006-01-31

申请人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

发明人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

IPC分类号： C07K14/82 ,  C07K16/30 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  C12P21/04

CPC分类号： C07K14/82 ,  C07K14/4748 ,  C07K16/3046

摘要： Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-001蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-001与异常发育和生长有关，可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-001表达或活性的化合物的方法，包括：使候选化合物与TAT-001接触并检测所述化合物与所述TAT-001之间是否存在结合，或 检测TAT-001表达或活性的变化。 还包括用于鉴定调节TAT-001表达或活性的抗癌化合物和化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-001表达或活性的变化。